Prognostic Factors of Evens et al for a Patient with Post-Transplantation Lymphoproliferative Disease (PTLD)

Description

Evens et al identified prognostic factors for post-transplantation lymphoproliferative disease (PTLD) in patients with solid organ transplants. These can help to identify a patient who may benefit from more aggressive management. The authors are from Northwestern University, University of Chicago, Rush University and Loyola University.

74% of the patients received first-line rituximab. All patients had reduction in immunosuppression.

Parameters:

(1) central nervous system (CNS) involvement

(2) bone marrow involvement

(3) serum albumin

Parameters	Finding	Points
CNS involvement	absent	0
	present	1
bone marrow involvement	absent	0
	present	1
serum albumin	normal	0
	below the lower limit of normal (LLN)	1

prognostic score =

= SUM(points for all 3 parameters)

Interpretation:

• minimum score: 0

• maximum score: 3

• A higher score was associated with a worse prognosis.

Total Score	3 Year Progression Free Survival	3 Year Overall Survival
0	84%	93%
1	66%	68%
2 or 3	7%	11%

To read more or access our algorithms and calculators, please log in or register.

Prognostic Factors of Evens et al for a Patient with Post-Transplantation Lymphoproliferative Disease (PTLD)

Description

Specialty